PA
LKFT

Profund Advisors’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Profund Advisors’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,907
Closed -$271K – 1195
2020
Q3 		$271K Sell
1,907
-358
-16% -$59.7K 0.01% 726
2020
Q2 		$447K Buy
2,265
+418
+23% +$86.6K 0.02% 426
2020
Q1 		$362K Sell
1,847
-564
-23% -$121K 0.03% 438
2019
Q4 		$499K Buy
+2,411
New +$446K 0.02% 607

Other funds holding LKFT

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Profund Advisors's LKFT Position: Q4 2020 in Review

Profund Advisors sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2020, closing a stake of 1,907 shares — an estimated $271K sold.

Profund Advisors first reported a position in LKFT in Q4 2019 and held it in 4 quarters. The position peaked at $499K in Q4 2019. 116 funds tracked by Wall St. Rank hold LKFT as of Q4 2020.

  • Profund Advisors reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2020 after selling out during the quarter.
  • Profund Advisors sold 1,907 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2020, an estimated $271K.
  • Profund Advisors first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2019 and held it in 4 quarters.
  • Profund Advisors's Lakefront Biotherapeutics American Depositary Shares position peaked at $499K in Q4 2019.
  • 116 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2020.

Based on Profund Advisors's 13F filing for Q4 2020, filed 9 Feb 2021.